R&D News | pharmaphorum

News

GSK to quit Stevenage for new R&D site in Cambridge

In a major shake-up of its UK operations, GSK is building a brand new R&D centre in Cambridge and transfer operations there from its Stevenage campus.

News

Severino takes the helm at Sarepta after turbulent spell

Around five months after long-serving CEO Doug Ingram said he was stepping down, Sarepta has named industry veteran Michael Severino to replace him.

News

IPO in wooden blocks on table with green foliage blurred in background

Scribe raises $155m in IPO, as Apnimed pitches for $150m

Gene-editing specialist Scribe becomes the 14th biotech to list on the Nasdaq this year, as sleep apnoea drug developer Apnimed prices its listing.

News

Chris McDonald replaces Vallance as UK science minister

Chris McDonald has been named the next UK Minister for Science, following the resignation of Patrick Vallance last week.

News

Argenx pens $2.2bn deal to buy autoimmune biotech Forte

Netherlands- and Belgium-based argenx has agreed to buy US biotech Forte Bio for up to $2.2bn, bolstering its autoimmune disease pipeline.

News

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.

GSK to quit Stevenage for new R&D site in Cambridge

Severino takes the helm at Sarepta after turbulent spell

Scribe raises $155m in IPO, as Apnimed pitches for $150m

Chris McDonald replaces Vallance as UK science minister

Argenx pens $2.2bn deal to buy autoimmune biotech Forte

Ipsen' Bylvay fluffs its lines in biliary atresia trial

ESMO26: Lowering toxicity, extending lives, with Syncromune

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks